Close Menu

This article has been updated to correct the number of Foundation Medicine's biopharmaceutical partnerships and a statement regarding the sensitivity of its liquid biopsy test.

NEW YORK – Natera's recent deal with Foundation Medicine to develop personalized cancer monitoring assays will allow it to piggyback on the Roche subsidiary's dominant market share in tumor genomic profiling to establish its Signatera test for use in advanced cancer patients, while continuing to pursue other opportunities for the test on its own.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.